Predicting Survival After Impella Implantation in Patients with Cardiogenic Shock: The J-PVAD Risk Score
European Journal of Heart Failure · 2025
DOI: 10.1002/ejhf.3471 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Heart Failure, 2025. Verfasst von Toru Kondo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Heart-Assist Devices, Registries, Shock, Cardiogenic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
Impella has become a new option for mechanical circulatory support in patients with cardiogenic shock (CS); however, prognostic models for patients after Impella are lacking. We aimed to identify the factors that predict in-hospital mortality in patients with CS requiring Impella and develop a new risk prediction model. Methods and results We utilized the J-PVAD registry, which includes all cases where Impella was implanted in Japan. Two-thirds of the patients in the J-PVAD registry were randomly assigned to the derivation cohort (n = 1701), and the other third was assigned to the validation cohort (n = 850). A backward stepwise logistic regression model was developed to identify factors associated with in-hospital mortality. In the derivation cohort, 956 patients were discharged alive, and 745 patients (43.8%) died during hospitalization. Among 29 candidate variables, 12 were independently associated with in-hospital mortality and were applied as components of the risk model, including age, sex, body mass index, fulminant myocarditis aetiology, cardiac arrest in hospital, baseline veno-arterial extracorporeal membrane oxygenation use, mean arterial pressure, lactate, lactate dehydrogenase, total bilirubin, creatinine, and albumin levels. The comparison of predicted and observed in-hospital mortality according to the 7th quantiles using the J-PVAD risk score showed good calibration. The area under the curve for the J-PVAD risk score was 0.76 (95% confidence interval 0.73–0.78). In the validation cohort, the J-PVAD risk score showed good calibration and discrimination ability.
Conclusions
The J-PVAD risk score can be calculated using variables easily obtained in routine clinical practice. It helps the accurate stratification of mortality risk and facilitates clinical decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Cardiac surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
ORCID-Profile: Toru Kondo
Zitieren
APA
Kondo, T., Yoshizumi, T., Morimoto, R., Imaizumi, T., Kazama, S., Hiraiwa, H., Okumura, T., Murohara, T., & Mutsuga, M. (2025). Predicting Survival After Impella Implantation in Patients with Cardiogenic Shock: The J-PVAD Risk Score. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3471
Vancouver
Kondo T, Yoshizumi T, Morimoto R, Imaizumi T, Kazama S, Hiraiwa H, et al. Predicting Survival After Impella Implantation in Patients with Cardiogenic Shock: The J-PVAD Risk Score. European Journal of Heart Failure. 2025. doi:10.1002/ejhf.3471
BibTeX
@article{Kondo2025,
author = {Kondo, Toru and Yoshizumi, Tomo and Morimoto, Ryota and Imaizumi, Takahiro and Kazama, Shingo and Hiraiwa, Hiroaki and Okumura, Takahiro and Murohara, Toyoaki and Mutsuga, Masato},
title = {Predicting Survival After Impella Implantation in Patients with Cardiogenic Shock: The J-PVAD Risk Score},
journal = {European Journal of Heart Failure},
year = {2025},
doi = {10.1002/ejhf.3471}
}
EUVIMED